Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03974438
Other study ID # S-20190101
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 19, 2019
Est. completion date September 14, 2020

Study information

Verified date September 2020
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to perform the first RCT investigating the possible effect of superficial dry-needling (SDN) - a special kind of acupuncture used for PHN. The participants will be divided into two groups. Group A, the intervention group will receive SDN in the area of pain. Group B, the control group will receive a sham procedure.


Description:

The aim of this study is to investigate the possible effect of SDN on PHN. The study population consists of patients with chronic pain after herpes zoster.

The study is a controlled double-blinded randomized study. The participants will be divided into two groups, group A, the intervention group, will receive SDN in the area of pain. Group B, the control group will receive a sham procedure. The procedure will take place at the out-patient clinic at Odense University Hospital. The plan is to include 40 patients (20 in each group).


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 14, 2020
Est. primary completion date September 14, 2020
Accepts healthy volunteers No
Gender All
Age group 55 Years to 75 Years
Eligibility Inclusion Criteria:

- Age between 50-75 years.

- Pain in the dermatomal area of the previous outbreak of HZ.

- Pain located to a dermatome originating from the thoracic or lumbar spine.

- At least six months since the outbreak.

- Understands the purpose of the study and is able to give consent.

Exclusion Criteria:

- A psychiatric illness affecting participation in the study.

- Active cancer

- Pregnancy

Study Design


Intervention

Procedure:
Superficial dry needling / Acupunture
Se arm-description.

Locations

Country Name City State
Denmark Odense University Hospital Odense Funen

Sponsors (1)

Lead Sponsor Collaborator
Odense University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dermal pain [LEVEL OF PAIN] Questionnaire. Visual Analogue Scale (VAS). Patients will be asked to report on their average and maximum level of pain on a scale from 0-10. 1 month
Secondary Neuropathic pain [LEVEL OF PAIN] Neuropathic Pain Symptom inventory (NPSI), Questionnaire. NPSI consists of 12 items in total: 10 items investigates differential symptoms descriptors and 2 items evaluate spontaneous and paroxysmal spontaneous pain.
The tool evaluates mean pain intensity in the last 24h in a verbal numeric scale from zero (no pain) to 10 (worst imaginable pain). Total pain intensity score may be calculated by the sum of the 10 descriptors.
The descriptors are:
Burning, Squeezing, Pressure, Electric Shocks, Stabbing, Provoked by brushing. Provoked by pressure, Evoked by cold stimulation, Pins and needles, Tingling.
1 month
Secondary Quality of life [QUALITY OF LIFE/ SATISFACTION] Short Form 36 (SF-36), Questionnaire. Scoring the RAND 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per a scoring key. All items are scored so that a high score defines a more favorable health state. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. After this, items in the same scale are averaged together to create the 8 scale scores.
The eight health concepts are: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health.
1 month
See also
  Status Clinical Trial Phase
Completed NCT01426230 - Phase IV Study of FDA Approved, Once-Daily GRALISEā„¢(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia N/A
Terminated NCT01124097 - Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia Phase 3
Recruiting NCT04144972 - Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain N/A
Completed NCT03447756 - Titration Study of ABX-1431 Phase 1
Recruiting NCT06155487 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects Phase 1
Recruiting NCT06218784 - A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients. Phase 1
Completed NCT03584061 - Treatment of Chronic Postherpetic Pain With Fat Grafting N/A
Completed NCT01270828 - Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia Phase 3
Enrolling by invitation NCT06410222 - Predictive Models for the Treatment of Recurrent Herpes Zoster Neuralgia Following Spinal Cord Electrical Stimulation.
Recruiting NCT05754190 - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Completed NCT00475904 - A Comparison of EpiCeptā„¢ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN) Phase 2
Completed NCT03765697 - A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia Phase 3
Completed NCT01748877 - Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia Phase 2
Recruiting NCT06241820 - The Success of Lumbar Sympathetic Ganglion Block Using Lower Extremity Perfusion Index N/A
Not yet recruiting NCT06130514 - The Comparison of Sympathetic Blockade of Stellate Ganglion Block and Thoracic Sympathetic Ganglion Block N/A
Completed NCT03745404 - A Study With Lido-Patch and Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN) Phase 3